B
Byondis
Netherlands - Nijmegen
BiotechnologyFocus: Antibody-Drug Conjugates, Monoclonals
Byondis is a life sciences company focused on Antibody-Drug Conjugates, Monoclonals.
Neurology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
SYD1875
Solid TumorClinical Trials (1)
NCT04202705A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
Phase 1SYD985 + Niraparib
Solid TumorClinical Trials (1)
NCT04235101Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
Phase 1BYON4413
Relapsed / Refractory AMLClinical Trials (1)
NCT06359002Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
Phase 1Vic-trastuzumab duocarmazine
HER2-positive Breast CancerClinical Trials (1)
NCT04602117ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Phase 1BYON3521
Solid TumorClinical Trials (1)
NCT05323045A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
Phase 1SYD985
Solid TumorsClinical Trials (1)
NCT02277717First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients
Phase 1BYON4228 + Pembrolizumab
Solid TumorClinical Trials (1)
NCT06932952A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
Phase 1BYON4228 + Rituximab
LymphomaClinical Trials (1)
NCT05737628First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
Phase 1BYON5667 & SYD985
Metastatic Breast CancerClinical Trials (1)
NCT04983238Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
Phase 1/2SYD985
Endometrial CancerClinical Trials (1)
NCT04205630SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
Phase 2SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Brea
Metastatic Breast CancerClinical Trials (1)
NCT03262935SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 11 clinical trials